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Abstract
Whole genome sequencing was completed on 1,325 individuals from 602 families, identifying 27 million autosomal
variants. Genetic association tests were conducted for those individuals who had been assessed for one or more of 17
endophenotypes (N range = 802–1,185). No significant associations were found. These 27 million variants were then
imputed into the full sample of individuals with psychophysiological data (N range = 3,088–4,469) and again tested for
associations with the 17 endophenotypes. No association was significant. Using a gene-based variable threshold burden
test of nonsynonymous variants, we obtained five significant associations. These findings are preliminary and call for
additional analysis of this rich sample. We argue that larger samples, alternative study designs, and additional
bioinformatics approaches will be necessary to discover associations between these endophenotypes and genomic
variation.
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Five of the companion articles in this special issue describe
genome-wide association studies (GWAS) from a fixed genotyping
array with a prespecified set of 527,829 variants. Such genotyping
arrays are designed primarily to capture common variants, those
with a minor allele frequency, or MAF, greater than .05. The other
original research article in this issue (Vrieze et al., 2014) describes
an association study between the 17 putative endophenotypes and
rare nonsynonymous exonic variants specifically, which are vari-
ants in coding regions that affect protein structure. In the current
study, we extended these analyses by employing whole genome
sequencing in an attempt to discover nearly all single nucleotide
polymorphisms (SNPs) present in any given individual, including
those on the GWAS and exome arrays as well as tens of millions
of additional variants. Because all variants are directly mea-
sured and genotyped, this results in increased power for common
variants and the ability to test rare variants throughout the entire
genome on a far larger scale than the other articles in this special
issue.
Whole genome sequencing interrogates the entire genome to
discover and accurately genotype variants from across the allelic
spectrum, from private mutations possessed by a single person (or
family), to common variants genotyped on typical microarrays.
The past few years have seen significant advances in population
genetics and characterization of rare genomic variation, which
were only possible with genome sequencing technology. The 1000
Genomes Project, for example, combined exome and whole
genome sequencing to discover 38 million SNPs in 1,092 individ-
uals from 14 ancestral populations (1000 Genomes Project
Consortium, 2012). The Exome Sequencing Project (Fu et al.,
2013) and analogous exome sequencing projects (Nelson et al.,
2012) have extensively interrogated exonic regions of the genome
and characterized a wide diversity of rare coding variants. In the
present study, we found 27.1 million autosomal SNPs, 21.3 million
of which have minor allele frequency less than 5%. Almost none of
these 21 million variants were tested in the other articles of this
special issue.
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1000 Genomes, Exome Sequencing Project, ENCODE, and
many related projects represent breathtaking technological and
analytical achievements, delivering insight into molecular biology,
genomics, evolutionary history, migratory patterns, and disease
biology, to name a few (Lander, 2011). Genome sequencing has
been less widely used in the study of human behavior, with notable
exceptions including advances in the genetics of autism (Neale
et al., 2012; O’Roak et al., 2011) and schizophrenia (Fromer et al.,
2014; Purcell et al., 2014). These studies employed exome
sequencing, which interrogates only the exons for each of ∼20,000
protein coding genes throughout the genome. The exome is an
important, but small, section of the genome, comprising less than
2% of all sequence in the genome. The remainder of the genome,
colorfully referred to in the past as “junk DNA,” is everything but
that. Work by the ENCODE consortium (ENCODE Project
Consortium, 2012) and others have verified that noncoding DNA
harbors genetic variation critical to genomic function. While
coding variants can affect protein structure, which is undoubtedly
important, noncoding DNA can affect which, when, and how fre-
quently genes are expressed, termed “gene regulation” more
broadly. Indeed, early work suggests that a majority of disease-
associated variants are in noncoding regions, with regulatory
regions likely enriched for genome-wide significant variants
(Maurano et al., 2012; Pickrell, 2014). Exhaustively interrogating
genetic variation in coding and noncoding regions requires whole
genome sequencing.
In the accompanying papers in this special issue, we described
a variety of genetic association studies in a sample of 4,905 indi-
viduals using different genotyping technologies to identify variants
associated with 17 psychophysiological phenotypes (for an over-
view, see Iacono, Malone, Vaidyanathan, & Vrieze, 2014). These
endophenotypes include P300 amplitude, antisaccade direction
errors, startle eye blink magnitude and modulation by affective
stimuli, skin conductance level and responses in a habituation
paradigm, and measures of resting EEG.
Although some of these endophenotypes are robust candidates,
and despite the hope that endophenotypes would provide increased
power to detect associated genes, the investigations described in the
companion articles of this special issue yielded few significant
findings. In analyses of common variants, only antisaccade error
was significantly associated with an individual SNP (Vaidyanathan,
Malone, Donnelly et al., 2014). Tests of rare exonic variants also
produced one significant association, between a nonsynonymous
SNP in PARD3 and electroencephalogram (EEG) theta power
(Vrieze et al., 2014). Gene-based tests of common variants, which
aggregate the effect of all SNPs within a given gene into a single
score, yielded several significant associations. P3 amplitude was
associated with MYEF2 (Malone, Vaidyanathan et al., 2014), EEG
delta power was associated with three genes (DEFA4, DEFA6, and
GABRA1; Malone, Burwell et al., 2014), antisaccade performance
was associated with two genes on Chromosome 2—B3GNT7 and
NCL—and the aversive difference startle modulation score was
associated with the PARP14 gene on Chromosome 3. Gene-based
tests of rare exonic variants yielded one significant association with
the pleasant difference startle modulation score and PNPLA7
(Vrieze et al., 2014), which was not readily interpretable.
The present article appears last in this special issue because it is
our most comprehensive and most powerful attempt to discover
novel genetic loci associated with these endophenotypes. In this
article, we describe three primary analyses. First, we test for
association between 27 million autosomal SNPs and each of
the 17 endophenotypes in 1,706 individuals with whole
genome sequences. Second, we conduct gene-based tests of
nonsynonymous variants in these same 1,706 individuals. Third,
we use the combination of genotype arrays and sequences to
impute all 27 million variants into the full Minnesota Center
for Twin and Family Research (MCTFR) sample with
psychophysiological endophenotypes (N = 4,905) and conduct the
same single variant and gene-based burden tests in this larger
sample.
Methods
A schematic overview of the methodological sequence is displayed
in Figure 1.
Participants
Individuals were selected from the Minnesota Twin Family Study
(MTFS) for moderate-depth whole genome sequencing. While we
originally collected molecular genetic data from 7,845 individuals
in the MCTFR (Iacono et al., 2014), we undertook whole genome
sequencing for a subsample of 1,328 individuals due to prohibitive
costs. Of these, 1,325 individuals from 602 families passed quality
control checks and were available for association study. First, 1,038
individuals were sequenced as part of the NIDA Genes, Environ-
ment, and Development Initiative (GEDI; McGue et al., 2013).
Next, 304 individuals were sequenced as part of a study of bipolar
disorder (operating under the acronym BRIDGES and led by M.
Boehnke at University of Michigan and R. Myers at HudsonAlpha)
that is not yet completed and for which there are no currently
available published sources. Sample selection within the MCTFR
began by considering only individuals with self-reported European
ancestry confirmed by genome-wide principal components, as
described previously (Miller et al., 2012). The GEDI sample was
selected in an attempt to maximize power to detect associations
with measures of alcohol use and externalizing psychopathology
(see details in online supporting information). BRIDGES samples
had been selected from the MCTFR cohorts to serve as additional
controls in a case-control genetic association study of bipolar dis-
order. As such, these samples happened to have been screened for
major forms of psychopathology to be included in the BRIDGES
study. BRIDGES selection criteria were at least 23 years of age; no
history of mania, major depression, or alcohol dependence; and
no first-degree relative with a history of bipolar disorder or major
depressive disorder. In addition, the samples were matched
for northern European ancestry to other BRIDGES bipolar
cases using genetic principal components. Not all of these
GEDI- and BRIDGES-selected individuals participated in the
psychophysiology lab.
Of these 1,325 individuals, 381 were one member of a
monozygotic (MZ) twin pair. Zygosity has been validated in this
sample through questionnaire, in-person review of the appearance
of the twins by experts, anthropomorphic measurements, DNA
concordances for all fraternal twins, and DNA concordances for
many MZ twin pairs, resulting in a zygosity diagnosis error rate
well under 1%. To maximize the yield of phenotypic data, co-twins
of MZ twins who were sequenced were added to the sample.
Genotypes were simply copied from the sequenced MZ twin to
his/her unsequenced co-twin, under the assumption that the
sequence was identical between MZ twins. This is a reasonable
assumption here, especially for common and low-frequency SNPs,
because differences between members of an MZ twin pair would be
indistinguishable from sequencing errors at the sequencing depth
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obtained here (10×). For rare variants, specifically singletons,
copying genotypes from one MZ twin to the other will introduce
errors due to somatic mutations (Poduri, Evrony, Cai, & Walsh,
2013), which are present only in one MZ twin and not the other.
If we assume that each person carries 50 somatic SNP muta-
tions in their genome (Neale et al., 2012), and 3.5 million
SNPs (1000 Genomes Project Consortium, 2012), somatic
mutations will represent a genotype error rate of approximately
50/3,500,000 = .001% in the MZ twins only. In the context of the
present study, we suggest that the increase in power obtained by
adding 381 individuals outweighs the increased genotype error
expected from somatic mutations. Furthermore, we do not evaluate
singletons in our single variant tests. Therefore, somatic mutations
in the present study will only affect gene-based tests in the exome,
where we expect less than one somatic exonic mutation per
individual.
After copying genotypes for MZ co-twins, there were 1,706
total sequenced individuals for association analysis. As noted, these
individuals were selected to be sequenced based on phenotypic
characteristics that were independent of their having been assessed
in the psychophysiology lab. Because not all MCTFR participants
completed a psychophysiological assessment, overlap between this
sample and the sample for the psychophysiology GWAS used here
is incomplete. The actual number with both sequences and
psychophysiological measurements ranged from 802 to 1,185,
depending on the phenotype. See Table 1 for more complete infor-
mation on the study sample.
Endophenotypes
The endophenotypes examined here are listed below. An overview
of all measures is provided in Box 1 in Iacono et al. (2014), while
the accompanying five GWAS articles in this special issue provide
additional details about each measure, including laboratory pro-
cedures and evidence supporting each measure as a candidate
endophenotype.
• P300 amplitude (Malone, Vaidyanathan et al., 2014):
1. P3 event-related potential (P3)
2. P3 genetic factor (gP3)
• Antisaccade eye tracking error rate (Vaidyanathan, Malone,
Donnelly et al., 2014)
3. Antisaccade tracking error rate (SAC)
• Electrodermal activity (Vaidyanathan, Isen et al., 2014)
4. Skin conductance level (SCL)
5. Skin conductance response frequency (fSCR)
6. Skin conductance response amplitude (aSCR)
Figure 1. Schematic analysis overview. For additional details see Iacono et al., 2014.
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7. Electrodermal activity factor (EDA), a general factor derived
from SCL, fSCR, and aSCR
• Startle blink reflex and affective startle modulation
(Vaidyanathan, Malone, Miller, McGue, & Iacono, 2014)
8. Overall startle (STRTL)
9. Aversive difference startle modulation (aSTRTL)
10. Pleasant difference startle modulation (pSTRTL)
• Resting state EEG (Malone, Burwell et al., 2014)
11. Total EEG power (totPower)
12. Alpha EEG power (αPower)
13. Beta EEG power (βPower)
14. Theta EEG power (θPower)
15. Delta EEG power (δPower)
16. Alpha EEG power O1O2 (αPowerO1O2)
17. Alpha EEG frequency O1O2 (αFreqO1O2)
Whole Genome Sequences and Concordance with
Array Genotypes
All DNA samples used in this sequencing study were whole blood,
and were obtained from participants of the MTFS, which is
included in the MCTFR. All sequencing was done on Illumina
HiSeq technology with 100 or 150 base pair paired-end reads. An
introductory overview of sequencing methodology is provide in
Box 1, with a more complete description in the online supporting
information. Sequencing was conducted at two separate institu-
tions, the University of Michigan Sequencing Core and
the HudsonAlpha Institute of Technology. After mapping, duplicate
read removal, and clipping of overlapping paired-end reads,
average depth was 10.47. The variant-calling pipeline, Genomes on
the Cloud (GotCloud; Jun, Wing, Abecasis, & Kang, 2014), dis-
covered 27,103,144 autosomal biallelic SNPs in the sample as a
whole (see supporting information Table S1 for additional
summary information about the genotype calls).
Genotype concordance was tested between the sequence-based
genotypes and the array-based genotypes obtained by integrating
the 660W-Quad and HumanExome arrays, as described in detail in
a companion article to this special issue (Vrieze et al., 2014). All
1,325 directly sequenced individuals had array genotype data,
and autosomal genotypes showed 99.91% concordance between
the sequenced and array-based genetic variants. Array-based
genotyping technology is highly accurate, and this result indicates
that the sequence genotypes were also highly accurate. We expect
accuracy to decline for rarer genotypes, which can be seen in
Figure 2, where we display genotype concordance between the
sequence genotypes and array genotypes across the minor allele
frequency spectrum, from rare variants to common variants.
We also examined the power of our 10× sequencing to discover
rare genotypes on the integrated array. The 10× sequencing in this
sample discovered 7,567 of 10,328 singletons, or SNPs where the
rare allele is observed only once (73%), 7,322 of 8,745 doubletons
(84%), 8,367 of 8,809 tripletons (95%), and 3,886 of 3,966
quadrupletons (98%) on the integrated array. Of monomorphic
sites on the integrated array, sequencing erred in a small fraction of
instances, calling 2,515 of 150,329 monomorphic sites on this
array as polymorphic (1.7%). While errors in variant discovery are
likely due to sequencing errors, it is also possible that these errors
are due to incorrect genotype calls on the integrated array, which
can be more challenging for rare variants. In summary, 10× whole
genome sequencing does reasonably well in genotyping singletons
and other rare variants.Ta
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Box 1: Steps in Whole Genome Sequencing
Overview The goal of sequencing is to identify all the polymorphic variation in an individual genome. The genome comprises three
billion base pairs, the vast majority of which are the same for everybody. Sequencing attempts to “read” the 6 billion letters (A,C,T,G)
in a person’s genetic code to identify base pairs that show polymorphism when one person is compared to another. It’s not possible to
read the entire sequence in one sweep through the genome; to make the task manageable, the DNA is sheared into small fragments, each
of which is read separately. The many fragments then need to be linked to each other to reconstruct the genetic code for that individual,
a process that is guided by a reference genome, which can be thought of as a single complete genome. Because genotyping errors are
made reading the code and in reconstructing a person’s genome from the fragments, this process is repeated with the number of
repetitions referred to as sequencing depth. With enough repetitions, it is possible to distinguish errors from true genomic variation. The
Illumina sequencing protocol followed in the laboratory for this project proceeded in several steps. These steps are detailed in greater
precision in the Supplementary Materials.
Library preparation, barcoding, and multiplexing First, each participant’s DNA is sheared into small fragments, which are
pooled together to form a DNA “library” for each individual. Each fragment is joined (ligated) with a unique DNA barcode to
link it to the correct participant. These libraries are then multiplexed—they are pooled together, divided and spread out over
several flowcells, which are physical lanes in which the DNA fragments move through the sequencing machine to be
sequenced. Once the library is multiplexed and put through the flowcell, the sequencer “reads” the DNA fragments (and
barcodes), ultimately producing files containing the reads and participant IDs in standard Sanger FASTQ format (see “Read
Mapping” below).
Contamination detection DNA contamination occurs when the participant’s tissue sample or DNA sample is accidentally mixed with
DNA from another person or a different organism. In our experience DNA contamination is common, and can seriously affect the results
of sequencing or genotyping experiments. We used verifyBamID (Jun et al., 2012) to detect contamination before read mapping or other
computationally expensive steps, so that contamination problems could be detected immediately and communicated to the sequencing
lab for rectification.
Read mapping The FASTQ file format (Cock, Fields, Goto, Heuer, & Rice, 2010) contains each read (essentially just strings of As, Cs,
Ts, and Gs) combined with information about the quality of each base. (It is well-known, for example, that bases at the beginning of
a read are more reliable than the end of a read.) At this point all one knows is that a particular read came from a particular participant,
thanks to the barcode, but it is unknown where in the genome the read was taken. Read mapping, or read alignment, is a process of
figuring out where a read came from in a participant’s genome.
The mapping process is complex but basically it takes each read and efficiently scours a reference genome to find a location
that matches the read (Li & Durbin, 2010). For the reference genome we used hs37d5, which can be thought of simply as a
single person’s entire genome laid out in order by chromosome and position. This particular reference genome also contains
“decoy sequences”, which include a variety of non-human or known problematic sequences commonly observed in sequencing
experiments. These decoys draw problematic reads to them, avoiding mismatching problem reads to erroneous locations in the
genome.
The mapping process must be tolerant of some discrepancies between the reads from our participants’ DNA samples and the
reference genome, because we expect our participants’ genomes to differ from the reference in millions of places. If mapping is too
tolerant, however, reads will be unable to be uniquely mapped to positions in the reference. (A difference between the participants
and the reference could be an error in either, but it also could be naturally occurring genetic variation.) Mapped reads are stored in
BAM files, which among other things contain a genomic position, the read at that position, and a score providing information about
the mapping quality and read quality.
Genotype calling With BAMs in hand we can proceed to genotype calling, the procedure used to decide, for each individual, what
genotype is present at a particular location in the genome. The most common approach for genotype calling is termed “multi-sample”
calling. The benefit of multi-sample calling is that to determine if a particular genomic position shows variation in a sample (is
polymorphic), it uses all read information for that site, across all participants, where each site in each participant may have been read
multiple times. So, for 10x sequencing we expect, for any given participant at any given genomic position, that they will have 10 reads
covering that position. If there are 1000 participants, then looking across participants we expect 10,000 reads at any given site, providing
high power to detect genetic variation at that site in the genome.
Once all the variant sites across all participants have been discovered, we proceed to estimate whether any given participant is
homozygous for the reference allele (i.e., the base that exists in the reference genome), heterozygous, or homozygous for a non-
reference allele (also referred to as homozygous alternate), with the non-reference allele simply being any allele not present at that
position in the reference genome.
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Genotype Imputation
As noted, not everyone in the sequenced sample of 1,706 indi-
viduals had psychophysiological data. The sequenced individuals
who had psychophysiological data for any given endophenotype
were a subset of the full 4,905 individuals with psychophysiology
data included in the other articles of this special issue (see
Figure 1 in Iacono et al., 2014). In addition to conducting asso-
ciation analyses in the sequenced individuals, we also attempted
to utilize all available psychophysiological data from as many
participants as possible. To do this, we imputed the 27 million
sequenced variants into the full array genotyped sample. In impu-
tation, one uses the more complete sequence information to fill in
the many millions of variants that were not included on a par-
ticular genotype array. Imputation is well known to increase
power for association and improve resolution of fine-mapping
efforts to pinpoint likely causal variants (Howie, Fuchsberger,
Stephens, Marchini, & Abecasis, 2012; Li, Willer, Ding, Scheet,
& Abecasis, 2010).
The imputation reference haplotype panel (e.g., 1000 Genomes
or, in this case, our sequences) is a critical component of
imputation. This is especially true for imputation of less common
variants, which is highly sensitive to the degree of ancestry
matching between the genotyped sample (to be imputed in) and
the reference haplotype panel (e.g., 1000 Genomes), as well as the
number of individuals in the reference haplotype panel. The
number of individuals in the panel is important because imputation
accuracy is in part a function of how many copies of a variant exist
in the haplotype panel. If only one copy exists (i.e., a singleton),
that variant will likely be difficult to impute accurately. One simple
way to increase the number of copies of a variant is to increase the
number of individuals in the haplotype panel. Since the number of
individuals of European ancestry sequenced in the MTFS was over
three times larger than the number of individuals of European
ancestry in 1000 Genomes, we expected the use of our MTFS
haplotype reference panel to provide significantly greater imputa-
tion accuracy over 1000 Genomes.
Through imputation, we were able to take advantage of the
moderate-depth sequences we generated, and the wealth of genetic
information contained in them: over 27 million autosomal variants,
many of which are rare. The first step was to phase the array
genotypes for the full sample of 7,278 genotyped individuals in the
MCTFR (excluding ungenotyped MZ co-twins). We used the full
Variant filtering A significant minority of variant sites discovered in genotype calling are false-positives. There are biases and errors
in the sequenced reads themselves, in the mapping process, and these errors affect variant calling. At the variant filtering stage one
evaluates a wide variety of variant properties, such as mapping quality, read depth at that site, or allele balance. One approach would
be to simply filter out variants that have, for example, low quality, low (or implausibly high) depth, and/or strand bias (e.g., the alternate
allele is always found on one DNA strand and not the other). This approach, while straightforward, is far from satisfactory. Therefore,
we used a support vector machine to simultaneously consider and weight all aspects of variant quality in deciding whether a variant is
good or bad (Jun, Wing, Abecasis, & Kang, 2014).
LD refinement In some cases, these per-individual genotype calls will be made with little read information because, just by chance,
there will be some sites in the genome that, for some individual, have no reads or a very small number of reads, while other sites have
many more reads. To overcome this limitation we “borrow” information from neighboring variant sites taking advantage of the
linkage disequilibrium structure of the genome, similar to what is done in genome imputation (Browning & Browning, 2009; Howie,
Fuchsberger, Stephens, Marchini, & Abecasis, 2012; Li, Willer, Ding, Scheet, & Abecasis, 2010). As a result, genotype calls based
on even low depth sequencing are highly accurate for common variants, as evidenced in the 1000 Genomes project, which had ∼4x
depth genome-wide (1000 Genomes Project Consortium, 2012).
Figure 2. Discordance rates between the integrated array genotypes and
sequence genotypes. This plot provides a description of the accuracy of
the genotype calls from whole genome sequencing. The bar chart along the
bottom gives the fraction of genotypes that were homozygous reference
(HomRef), heterozygous (Het), and homozygous alternate (HomAlt), for
the full range of possible nonreference allele counts. For example, if an
individual in the study was called homozygous reference on the array (i.e.,
homozygous for the same allele that exists on the reference genome
GRCh37), then the red dots give the rate at which that individual was called
something other than homozygous reference in the sequence data. For
SNPs with a nonreference allele count of 1–10, the sequence error rate was
approximately 1 in 10,000. For SNPs with nonreference allele count of
1,500 (MAF ∼50%), the sequence error rate was approximately 1 in 1,000.
Similarly, if an individual was called heterozygous for some SNP on the
array, then the green dots give the rate at which individuals were called
heterozygous in the sequences. For a site with nonreference allele count of
1–10, the sequence error rate was about 20%. (Note that this 20% is based
on only 141 genotypes—individuals homozygous for an alternate allele are
rare.) For sites with nonreference allele counts of 1,500, the rate was a little
over 1 in 1,000. In general, sequencing was highly accurate, with accuracy
falling off for the rarest variants.
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MCTFR sample in order to improve phasing accuracy with
SHAPEIT (Delaneau, Zagury, & Marchini, 2013) by using as much
family information as possible.
For all single variant association analyses, we used the full set
of 27 million imputed SNPs. For gene-based burden tests, we
restricted the set of imputed variants to those imputed with
sufficient accuracy, as judged by an imputation minimac RSQ > .3
(Li et al., 2010).
Evaluation of Imputation Accuracy
We evaluated imputation accuracy in several ways. First, we com-
pared minimac RSQ values between imputation results with MTFS
sequences and 1000 Genomes sequences. Minimac RSQ is an
estimate of the true squared correlation between the imputed allele
dosage and the true allele dosage, based on the hidden Markov
model in minimac (Li et al., 2010). RSQ > .3 is a conventional
cutoff to conclude a variant has been imputed with sufficient accu-
racy. For instance, variants with RSQ ≤ .3 are commonly excluded
in association studies.
In order to provide a more direct comparison of imputation
accuracy between the MTFS and 1000 Genomes reference
sequences, we compared imputation accuracy using dosage R2,
the squared Pearson correlation between the minor allele genotype
count from rare variants on the exome array and the imputed dosage
for the intersection of sites in the MTFS sequences, 1000 Genomes,
and the exome chip. In this comparison, we restricted phasing and
imputation to Chromosome 20 from the 660W-Quad only. We
purposefully excluded all variants from the exome array during
phasing and imputation, imputed all the exome chip variants that
were discovered through sequencing, and then evaluated the accu-
racy of that imputation. We restricted this subsample to individuals
with European ancestry, just as we have throughout this special issue
in all association analyses. Finally, we included only one member of
each MZ twin pair, because the other member is entirely redundant
for purely genetic analyses such as imputation (recall the genotypes
are copied from the genotyped twin to his/her co-twin). This resulted
in a subsample of 6,610 individuals of European ancestry for 1,369
SNPs, for the sole purpose of evaluating imputation accuracy for
rare variants.
Follow-Up Genotyping
Several imputed variants in an intron of the ALK gene were sig-
nificantly associated with EEG alpha frequency. We genotyped
these variants in 48 DNA samples from individuals in 12 fami-
lies, including 13 putative carriers of the rare allele in at least one
site, 10 of whom had endophenotype data. For each sample, 1 ul
DNA at 20 ng/ul was genotyped in a 25 ul reaction along with
12.5 ul TaqMan Universal PCR Master Mix (Life Technologies,
Grand Island, NY), 0.625 ul of 40X primer/probe mix, and
10.875 ul water. We used a manufacturer-recommended PCR
program: an initial step of 95°C for 10 min, then a 15-s step at
92°, and a 1.5-min step at 60°. Steps 2 and 3 were cycled through
50 times. Each of the four polymorphisms was amplified sepa-
rately, and the allelic variants for each polymorphism were
labeled with VIC and FAM 5′-fluorescent labels. We used an
Applied Biosystems PRISM sequence detection 7500 Real Time
PCR System to discriminate between alleles, which uses an
optical reading of fluorescent markers following a 1-min period
of activation at 60°C to assess the amount of probe sequence
product.
Results
Association Analysis in Individuals with Endophenotype Data
We conducted single variant tests on inverse normalized pheno-
types in EPACTS using EMMAX (Kang et al., 2010), which
produces a genetic kinship matrix that is used to correct for popu-
lation stratification and familial structure. Depending on the
endophenotype, there were approximately 14 million variants with
a minor allele count greater than three that were tested for associa-
tion with an endophenotype, resulting in an approximate
Bonferroni correction of 4 × 10−9 to obtain genome-wide signifi-
cance. At this threshold, no single variant was significant. Q-Q
plots and Manhattan plots for each endophenotype are available in
the supporting information.
In order to evaluate whether the aggregate effect of rare
nonsynonymous variants in genes produced associations with
the endophenotypes, we conducted burden tests using a variable
threshold count-based method (Price et al., 2010) and the sequence
kernel association test (Wu et al., 2011). Variants were annotated
using EPACTS (Kang, 2014) against GENCODE v11. All missense
and nonsense nonsynonymous SNPs, including essential splice
SNPs, were included in all gene-based tests. Depending on
the phenotype, we tested from 15,816 (P3 genetic factor) to 16,394
(antisaccade) genes that had at least two nonsynonymous variants
and a burden allele count of at least three, considering only variants
with MAF < .05, resulting in Bonferroni corrections of ∼3.2 × 10−6.
No gene was associated with any endophenotype at these levels of
significance.
Genotype Imputation with Sequences into Full Sample
We then imputed into these 7,278 phased haplotypes with the
MCTFR sequences and again separately with the 1000 Genomes as
the haplotype reference panels, using minimac with 200 states and
5 rounds (Howie et al., 2012). Imputation accuracy statistics for
both reference panels are provided in Table 2. While it may appear
that the MTFS sequences perform better than 1000 Genomes
because higher minimac RSQ values were obtained, a direct
comparison using the summaries in Table 2 is not entirely appro-
priate. The 1,325 sequenced individuals are included in these
estimates and bias them upward—that is, for 1,325 individuals we
used their own sequences to conduct imputation into their array
genotypes.
Evaluation of Imputation Accuracy with Dosage R2
For 333 common variants (MAF > 5%), imputation accuracy was
comparable between 1000 Genomes and MCTFR sequences
(dosage R2 = .905 and .952, respectively). For less common vari-
ants, with MAF ≤ 5%, imputation using the MCTFR sequences
performed noticeably better, resulting in increases of .2–.3 in the
dosage R2 value for SNPs with MAF < 1%. The results are dis-
played in Figure 3, where one notices that MCTFR outperforms
1000 Genomes for each minor allele frequency bin.
Association Results with Imputed Genotypes
We conducted single variant and burden association tests using
the imputed genotypes, in the full sample of individuals with
psychophysiological phenotypes reported on in the companion
articles in this special issue (N ranging from 3,088 to 4,469). Q-Q
plots and Manhattan plots are displayed in the supporting infor-
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mation. Depending on the phenotype, the number of SNPs with
an imputed dosage allele count of at least three ranged from
19,284,812 (P3 genetic factor) to 21,812,431 (antisaccade error),
resulting in Bonferroni corrections ranging from 2.6e-9 to 2.3e-9.
At these levels of significance, there were two variants
(chr2:29994680 and chr2:29978404) significantly associated with
alpha EEG frequency at O1O2. However, follow-up genotyping
found an imputation error in marker chr2:29994680, which
affected dosage counts for both variants. After accounting for this
error, the p values for these SNPs dropped to nonsignificant
levels. The results are displayed in Table 3, which includes all p
values less than the conventional genome-wide significance
threshold of 5e-8, even though p < 5e-8 is not genome-wide
significant in this context.
We conducted variable threshold gene-based burden tests for all
nonsynonymous variants imputed with MTFS sequences with
minimac RSQ > .3, a conventional cutoff. After considering only
genes that had at least two called SNPs with a burden allele count of
three or greater, the number of genes tested ranged from 16,070 to
16,263, with corresponding Bonferroni cutoffs of ∼2.8e-6. Four genes
were significantly associated with an endophenotype and are dis-
played in Table 4. The variable threshold collapsing and multi-
variante count (VTCMC) test identified two genes, annexin A3
(ANXA3) associated with antisaccade, and solute carrier family 27
(fatty acid transporter) member 6 (SLC27A6) associated with aver-
sive difference startle modulation. The SKAT test also identified two
genes, GBX2 and KIF18A, as significantly associated with EEG beta
power and pleasant difference startle modulation, respectively.
Discussion
We reported results for association tests between psychophy-
siological endophenotypes and SNPs discovered through whole
genome sequencing. Association results identified no genome-wide
significant variants, after accounting for the many millions of tests
conducted here. Gene-based burden tests identified four potential
signals, in ANXA3, GBX2, KIF18A, and SLC27A6 genes, associ-
ated with antisaccade error, EEG beta power, pleasant difference
startle modulation, and aversive difference startle modulation,
respectively. ANXA3 is part of a signal transduction pathway and
the regulation of cell growth, and has not been associated previ-
ously with endophenotypes or phenotypes relevant to antisaccade
performance. GBX2, gastrulation brain homeobox 2, is involved in
brain development in the mid/hindbrain region, and controls the
proper expression of other genes during embryogenesis. The GBX2
association was marginally significant, based on only two relatively
poorly imputed singletons, and should be interpreted with addi-
tional skepticism until replication. SLC27A6 is a solute carrier not
expressed in the brain and KIF18A is involved in chromosome
congression during mitosis and meiosis, limiting interpretative
speculation about their roles in modulated startle.
Whole genome sequences provide an immense amount of infor-
mation about genomic variation that is only beginning to be tapped
in the present article, and we consider the present results prelimi-
nary. Nevertheless, the results suggest that hunting for genes
associated with complex phenotypes, including complex endo-
phenotypes, will require alternative approaches to those considered
here. The present article is the largest and most comprehensive test
of genetic association for psychophysiological endophenotypes
undertaken to date. The study sample is richly phenotyped and
genotyped, but clearly naïve single variant analyses and gene-based
tests with nonsynonymous annotation will not be sufficient to
Table 2. Imputation Accuracy into All Available Individuals of European Ancestry
Imputation with MTFS sequences Imputation with 1000 Genomes Aug 2011 release
N Mean RSQ RSQ > .3 N Mean RSQ RSQ > .3
< .001 11,874,879 .479 78.8% 19,028,251 .278 35.5%
MAF [.001–.005) 5,137,513 .639 95.8% 6,641,963 .456 64.9%
MAF [.005–.01) 1,325,092 .764 98.5% 1,690,255 .568 79.7%
MAF [.01–.05) 2,673,865 .862 99.0% 3,022,145 .726 90.1%
MAF ≥ .05 5,872,931 .965 99.5% 6,604,512 .911 97.3%
Note. SNPs were selected using the 1000 Genomes imputed minor allele frequency. RSQ = minimac-estimated quality metric based on the imputation hidden
Markov model; RSQ > .3 = percentage of variants with minimac RSQ greater than .3, a conventional threshold used to discard poorly imputed variants.
Figure 3. Imputation accuracy comparison between MTFS sequence and
1000 Genomes reference panels. This plot provides a comparison of the
imputation accuracy on Chromosome 20 obtained with 1000 Genomes
compared to MCTFR sequence. Plotted in solid lines is the squared Pearson
correlation between the imputed dosage and the genotyped minor allele
counts for a range of allele frequencies, using MCTFR sequences (black)
and 1000 Genomes sequences (blue) as imputation reference panels. The
number of SNPs contributing to each window are given in red, and each
window was centered on each dot in the red line. The plots show that the
MTFS reference panel provides imputation results for all MAFs, and
especially better results for less common alleles.
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discover strong genetic signals in a sample of this size. The results
should bring pause to arguments about the utility of endo-
phenotypes, or intermediate phenotypes, to dramatically increase
power to detect individual variants or genes associated with them,
or with their relevant clinical phenotypes. Of course, it is possible
and perhaps likely that some endophenotypes will serve this
purpose in samples of this size, but those are not among our 17.
The endophenotypes described in this special section were ini-
tially conceived and selected two decades ago, around the time
the Human Genome Project began. Nevertheless, many of our
endophenotypes were as much measures of basic brain function
then as they are now. We therefore contend that the present findings
are highly relevant to current endophenotypic research including
exciting new efforts to identify neural systems involved in behavior
and psychiatric disorder such as the RDoC (Insel et al., 2010),
insofar as investigators attempt to understand the genetic architec-
ture of those systems.
In aggregate, there were fewer significant and biologically plau-
sible associations than might be expected, if one assumes that
endophenotypes will provide greater power to identify genes rel-
evant for psychiatric disease or behavioral traits. Given the results
reported in this special issue, this assumption may be unrealistic for
these psychophysiological endophenotypes, although one might
contend that they remain relatively complex and genetically distal
measures of basic brain function and task-related brain activity. At
the very least, one may conclude the endophenotypic increase in
power to detect genes is not great enough to be observed in a
sample of the size reported here (N < 4,500).
There was some reason to expect that these endophenotypes
would provide sufficient power to detect at least a handful of
variants in our sample of between 3,088 and 4,469 individuals.
More direct measures of biological function, for example, have
shown greater power in detecting associated loci in prior work. As
we noted in the accompanying method paper (Iacono et al., 2014),
genetic association studies of bone mineral density, cholesterol
levels, and QT interval all identified genetic associations in samples
of fewer than 5,000 individuals (e.g., see Figure 2b in Visscher,
Brown, McCarthy, & Yang, 2012). In contrast, investigations of
more distal phenotypes, such as height and body mass index,
required closer to 20,000 individuals before any significant and
replicable loci were discovered.
Limitations and future directions. The present article represents
a first and preliminary step. We have conducted here a variety of
obvious initial analyses but much remains to be done with the
data available here, by us and by external investigators interested
in working with these data. The present sequencing study is
ongoing. We are expanding our sample: increasing the number of
sequencing reads for a large minority of individuals, refining geno-
type calls, and extending variant calling to indels, structural vari-
ants, and the sex chromosomes. Structural variants and indels have
been implicated in autism (Glessner et al., 2009) and schizophrenia
(Rees et al., 2014), and represent an additional source of genetic
variation of potential value. Plans are also underway to evaluate
naturally occurring knockouts (e.g., stop-gains) in great detail in
individuals who are homozygous, heterozygous, or compound
heterozygous. Indeed, even in the present study with 1,325
sequences there were 54 stop-gain variants (almost entirely rare) in
195 autosomal candidate genes identified by the NIDA Center for
Genetic Studies discussed elsewhere in this special issue (https://
zork5.wustl.edu/nida/neurosnp.html). Finally, we will leverage the
whole genome sequences to conduct enrichment tests of regulatory
regions using publicly available epigenomic data. Each of these
endeavors is a natural extension of the results reported here.
One major, but necessary, obstacle encountered in the current
article is the strong multiple test correction. It is tempting to bypass
this restriction by conducting targeted analyses of candidate genes,
correcting only for the number of tests conducted on those genes.
Indeed, targeted sequencing has produced important results in prior
work (Bevilacqua et al., 2010), but it remains to be seen whether new
sequencing technologies will overcome the known limitations of the
candidate gene approach (Hirschhorn, Lohmueller, Byrne, &
Hirschhorn, 2002; Sullivan, 2007). Without strong a priori evidence
for a candidate gene–phenotype association, and clear genomic
Table 3. Single Variant Results for Imputed Variants with p < 5 × 10−8 and Imputation RSQ > .3
Phenotype Chr Base Pair Ref Alt N Dosage AC RSQ
Genotype counts
(REF/HET/ALT)* MAF Beta Bonferroni threshold p value
aSCR 14 78792316 C T 4,102 1,552.36 .984 2713/1222/167 .1892 −0.17 2.3e-9 3.7e-8
SAC 2 232296082 C T 4,469 2,751.04 .989 2138/1910/421 .3078 0.14 2.3e-9 3.8e-8
STRTL 2 81204732 A C 3,323 53.25 .645 3278/45/0 .0080 −1.06 2.5e-9 3.0e-9
aSTRTL 3 117162298 C T 3,321 11.9 .747 3310/11/0 .0018 −1.86 2.5e-9 3.2e-8
aSTRTL 3 122371714 G A 3,321 383.07 .994 2956/346/19 .0477 −0.29 2.5e-9 4.0e-8
pSTRTL 2 218395145 T C 3,322 1,402.99 .971 2060/1123/139 .2112 0.17 2.5e-9 4.1e-8
βPower 18 19453259 G C 3,948 5.31 .439 3946/2/0 .0007 −4.10 2.4e-9 1.4e-8
βPower 7 115086918 T G 3,948 3.51 .726 3944/4/0 .0004 −3.56 2.4e-9 3.1e-8
βPower 12 128908244 G A 3,948 530.5 .838 3435/501/12 .0672 0.31 2.4e-9 4.4e-8
θPower 4 6020367 G T 3,948 4,258.6 .945 832/1988/1128 .4607 0.14 2.4e-9 4.9e-8
αFreqO1O2 2 29943375 G A 3,966 10.35 .722 3957/9/0 .0013 2.00 2.4e-9 1.0e-8
αFreqO1O2 2 29946190 A T 3,966 10.37 .720 3957/9/0 .0013 2.00 2.4e-9 1.0e-8
αFreqO1O2 2 29978404 G T 3,966 10.57 .694 3957/9/0 .0013 2.00 2.4e-9 8.8e-9
αFreqO1O2 2 29994680 A G 3,966 10.80 .688 3956/9/0 .0014 2.00 2.4e-9 8.3e-9
αFreqO1O2 17 40076444 G A 3,966 42.78 .736 3922/44/0 .0054 1.00 2.4e-9 4.0e-8
Note. p values reported for αFreqO1O2 are computed taking into account follow-up genotyping described in the Method. Ref = reference allele reported on
GRCh37 reference genome; Alt = alternate allele, or nonreference allele; N = samples size with genotypes and phentoypes; Dosage AC = the number of
expected minor alleles determined from imputation, which helps account for statistical uncertainty in the imputation procedure; RSQ = minimac imputation
RSQ, a measure of imputation accuracy. A conventional RSQ threshold to exclude clearly bad variants is RSC < .3. MAF = minor allele frequency.
Beta = standardized effect size.
*Genotype counts are organized as homozygote REFerence/HETerozygote/homozygote ALTernate genotypes.
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function of candidate variants within that gene, we caution that
targeted approaches with relaxed statistical or experimental control
should be interpreted with circumspection until consistently repli-
cated. If statistical stringency or gene candidacy criteria were
relaxed, we would expect a bevy of false-positive association results,
and the use of valuable resources to falsify those erroneous findings.
The problem is compounded in whole genome sequencing by the
large number of protein-coding genes in the human genome and the
many different ways to annotate variants within and around these
genes. Despite these concerns, we believe that analysis of whole
genome sequence data is not complete until a variety of sensible
analyses are attempted and subjected to replication, including
detailed study of strong candidate genes as we have argued else-
where (Vrieze, Iacono, & McGue, 2012).
Conclusion
We tested 27 million SNPs for association with 17 endophe-
notypes in a moderately sized study sample. No single variant
was significant. Gene-based tests identified four associated genes,
and replication is required. The findings suggest that these
endophenotypes may not provide sufficient power to discover
individual variants or genes relevant to clinical phenomena, at
least in a sample of this size using the brute force analytical
methods presented here. However, additional analyses are under-
way and remain to be done, leveraging additional genomic vari-
ation, structure, function, and experimental design to test the
utility of this sample to detect genetic variants relevant for these
endophenotypes.
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